Further, mice given dexmedetomidine showed significantly lower tumor burden and TNF-α levels compared to the Control group 4 weeks after surgery, suggesting a possible role for dexmedetomidine to abrogate the SSR and therefore alleviate immunosuppression during the perioperative window. This evidence concerns the gene TNF and neoplasm.